The pharmaceutical giant, Merck, is set to pay $100 million in a settlement to NuvaRing users that said they were harmed as a result of using the product. The women specifically argue that the NuvaRing is associated with an increased risk of life-threatening blood clots, and that users were not adequately warned of this potential danger. The settlement money will be distributed between 3,800 women who used the NuvaRing who have filed lawsuits in federal and state courts.